• run with the bulls

    get your first month

    of hedgeye free


This Week In Hedgeye Cartoons

Our cartoonist Bob Rich captures the tenor on Wall Street every weekday in Hedgeye's widely-acclaimed Cartoon of the Day. Below are his five latest cartoons. We hope you enjoy his humor and wit as filtered through Hedgeye's market insights. (Click here to receive our daily cartoon for free.)




1. No Mirage (5/13/2016)

This Week In Hedgeye Cartoons - retail cartoon 05.13.2016


Despite Retail Sales numbers beating consensus estimates, the year-over-year growth numbers have been declining since the second half of 2014. Slower growth? That explains why retailers like Kohl's (KSS) and Nordstrom (JWN) got crushed this week. We reiterate our #ConsumerSlowing call. 


2. The Spin Cycle (5/12/2016)

This Week In Hedgeye Cartoons - The Cycle cartoon 05.12.2016


"While it should surprise no one who has been on the right side of the US economic, profit, and credit cycle call that the #LateCycle Sectors of the US Economy (Financials, Consumer Discretionary, Tech, Healthcare) are the biggest dogs for the YTD, the pace of the decline in the US Retail (XRT) sub-sector of consumer has caught many off-side this week," Hedgeye CEO Keith McCullough wrote in the Early Look this morning.


3. Precious Metals (5/11/2016)

This Week In Hedgeye Cartoons - gold cartoon 05.11.2016


It's been a tumultuous 2016 for investors but there's always a bull market somewhere. Gold is up more than 20% this year.


4. Dead On Arrival (5/10/2016)

This Week In Hedgeye Cartoons - earnings season cartoon 05.10.2016


A brief update on earnings season:

  1. 441 of 500 S&P 500 companies have reported their Q1 2016 numbers
  2. Aggregate SALES growth is DOWN -2.4% year-over-year
  3. Aggregate EARNINGS growth is DOWN -8.9% year-over-year
  4. Ex-Energy (EPS -109% y/y), Financials have EARNINGS DOWN -14.3% year-over-year
  5. Ex-Energy, Technology has EARNINGS DOWN -8.4% year-over-year 


5. An (Increasingly) Red Book (5/9/2016)

This Week In Hedgeye Cartoons - China cartoon 05.09.2016


Chinese equities were down hard overnight (Shanghai Comp down another -2.8% and -47% from 2015’s high) on terrible export (-1.8% y/y APR vs. +11.5% MAR) and import (-10.9% y/y APR vs. -7.6% MAR) data. To be clear, we’re not in the everything has “bottomed” camp.

Investing Ideas Newsletter

Takeaway: Current Investing Ideas: DE, HBI, LAZ, MDRX, FL, NUS, JNK, TIF, WAB, ZBH, ZROZ, XLU, MCD, TLT

Investing Ideas Newsletter - The Cycle cartoon 05.12.2016


Below are our analysts’ new updates on our fourteen current high conviction long and short ideas. As a reminder, if nothing material has changed in the past week which would affect a particular idea, our analyst has noted this. We will send CEO Keith McCullough’s updated levels for each ticker in a separate email.



To view our analyst's original report on Junk Bonds click here, here for Utilities and here for Pimco 25+ Year Zero Coupon US Treasury ETF.


On The Macro Show Friday, we provided an update on one of our three Q2 Macro Themes: #TheCycle. In summary, credit markets are one of the major beneficiaries (maybe the largest) of the reflation trade since February. While yield spread compression has been a positive for Long Bonds (TLT, ZROZ), a perceived monetary policy shift and a collapse in bond market volatility expectations have been a positive for Junk Bonds (JNK), but we don’t expect it to continue:


Investing Ideas Newsletter - 05.13.16 MOVE vs. Yield Spread


Current global macro positioning is squarely behind a continuation in the reflation trade as evidenced by commodity leveraged credit spreads, global macro futures and options positioning, and forward-looking volatility expectations. Below we show global macro futures and options positioning, which shows a market that is leaning long of commodities and short of U.S. dollars (yellow box):


Investing Ideas Newsletter - 05.13.16 contract Positioning


Where do we go from here?


Corporate credit as a % of GDP remains at cycle highs, capital markets activity has dried up significantly, and credit extension is tightening nationwide according the most recent Fed Senior Loan Officer survey:


Investing Ideas Newsletter - 05.13.16 credit cycle indicator


With growth continuing to slow alongside consensus positioning broadly, downside deflation risk is on the table. As we’ve highlighted on a daily basis, consumption growth and labor market growth peaked in Q1 2015 and both are slowing alongside a continued corporate profits slowdown. This mix:


  1. Smells like incremental deflation on the margin;
  2. Is a huge risk for high yield credit (JNK);


Did we mention TLT and ZROZ were up 4.4% and 2.1% respectively last week? Not bad with U.S. #GrowthSlowing.


To view our analyst's original report on Zimmer Biomet click here. 


Zimmer-Biomet (ZBH) presented at the BofA Healthcare Conference this week. Below are some select questions and answers from the presentation. On the one hand, it seems the analyst is asking ZBH to admit growth is going to be better than they are forecasting, both from volume and improving price trends.  But the CFO doesn’t bite. We would note that 2017 expectations have been rising in the last couple of months and assume 3% growth year-over-year, exactly at the mid point of management's 2-4% market expectation. On the CJR, they still don’t see it as a negative, but we are fairly convinced it will be.


Q: "Can you give us your best sense as to why things [the market in 1Q16] got a little bit better? Do you think it's sustainable? Just your view on recent volume trends would be very helpful."

A: “Our model continues to reflect a 2% to 4% type growth out over time.”


Q: In 1Q16 “pricing trends were a little bit better”

A: “I'd say that our view on that is, one, that it's probably a temporary phenomenon”


Q: Are these “growth rates … sustainable? Away from price and mix in the U.S., volumes are up 6%, 7%”

A: “Our view of the market continues to be in that low to mid single-digit range”


Q: “CJR, obviously, it's something that people have been talking an awful lot about, but I'll just make it a broad question. The fear for medical device investors is that this program could lead to could have a negative impact on volumes, sort of the cherry-picking aspects of it.”

A: “We do not have a view that says volumes will suffer as a result of CJR”



Investing Ideas Newsletter - zbh


To view our analyst's original report on McDonald's click here


For some perspective on the Macro environment and why we favor companies like McDonald's (MCD), here's an excerpt from the Early Look written by Hedgeye CEO Keith McCullough earlier this week:


"While it should surprise no one who has been on the right side of the US economic, profit, and credit cycle call that the #LateCycle Sectors of the US Economy (Financials, Consumer Discretionary, Tech, Healthcare) are the biggest dogs for the YTD, the pace of the decline in the US Retail (XRT) sub-sector of consumer has caught many off-side this week.


Taking a step back, don’t forget where US Consumers (70% of GDP) were at this time last year:


  1. US Employment Growth (NFP) was putting in a cycle peak
  2. US Consumer Confidence was putting in a cycle peak
  3. US Consumption Growth was putting in a cycle peak


Peak. Peak. #Peak!


And what happens when you start to lap the cycle peak? Well, instead of crappy Baby Boom capacity putting up mediocre (barely positive) same store sales at the peak, they look even crappier on the back side of the cycle."


That's why we like large-cap, low-beta, liquid companies like McDonald's in this tumultuous market environment. Case in point, earlier in the week, MCD hit an all-time high. Since we added the company to Investing Ideas, it is up almost 30%. 


Stick with it. Restaurants analyst Howard Penney reiterates his "road to $150" call, implyling more than 15% upside from here.


To view our analyst's original report on Hanesbrands click here, here for Tiffany, and here for Foot Locker.


On The Macro Show this morning, Hedgeye Retail analyst Brian McGough gave a sweeping overview of the many earnings misses in the sector this week. In addition to highlighting recent developments at companies on Investing Ideas, like Hanesbrands (HBI), Tiffany (TIF) and Foot Locker (FL), Brian discussed other high-conviction names he covers. Among them, his short Kohl's (KSS) thesis following it's lackluster earnings release and the subsequent -10% tumble shares. 


Additional topics of discussion included: why we’ve already seen more retail bankruptcies this year than in any full year in the last six; department store sales versus overall retail sales; and an update on e-commerce traffic.


Below is McGough's full presentation and the live Q&A with subscribers that followed.


Investing Ideas Newsletter - HETV investing ideas retail play

Click here to access the associated slides. 


To view our analyst's original report on Nu Skin click here


Based on 1Q16 numbers, we remain cautious on Nu Skin (NUS) for the following reasons:

  • For the second quarter in a row VitaMeal sales were down
  • The company is now seeing a decline in distributors across the world
  • The increase in revenue guidance was due to the change in FX
  • Increased earnings projections, but did not put cohesive story together on how they would achieve these results
  • At the same time the company guided down 2Q16 revenue growth from double digit growth on the last earnings call
  • Operating margin compression is staggering
  • Inventory growth was +3.7% versus sales declining of -8.7%
  • On 10/29/15 the company announced an aggressive repurchase authorization and increased it to $500 million.  The balance now stands at $427, barely buying any stock given the low price over the past six months.
  • The company compared the potential for ageLOC Me to Keurig Coffee Makers (lol) 


To view our analyst's original report on Allscripts click here. Below is an excerpt from an institutional research note written on Allscripts (MDRX) by Healthcare analysts Tom Tobin and Andrew Freedman.


Investing Ideas Newsletter - MDRX

we remain short mdrx in the position monitor


We spoke to a former Netsmart Salesperson to get a better understanding of the business and market opportunity, but also to see how great of a deal this really was for Allscripts.  We finished the conversation more positive about the quality of Netsmart's products, but more negative on the market opportunity. It also reinforced our initial view that the deal makes little strategic sense given core market overlap and lack of a clear end game.


We also view this as further evidence that Allscripts has all but given up on the ambulatory market, given that the Netsmart myEvolv EHR is technically a competing solution to Allscripts Professional in Behavioral Health.  Netsmart has three core products 1) Tier EHR for Substance Abuse 2) myEvolv EHR for Behavioral Health and 3) myAvatar EHR for Behavioral Health w/Inpatient. 

key takeaways

  • Substance abuse market saturated for Tier EHR; having a tough time selling those systems. Targeting mostly public and small independent facilities that are budget constrained and price sensitive.
  • Products too expensive and priced themselves out of the market; high-end of market saturated and had to diversify product portfolio and lower price to move downstream.
  • myEvolv was the best selling product, but cannibalized sales from higher price point myAvatar system; myEvolv can perform same functions, but doesn't have inpatient component. 
  • Netsmart was looking for a buyer for some time; "...already reached the height of their potential" and the reason why they were diversifying the business model, to make themselves more attractive.
  • Internal organization problems with a lot of employee turnover and lack of proper training for new sales employees.
  • Hit their revenue target for 2015, but missed bookings goal; most of the growth came from private equity funded acquisitions.
  • CareManager and CareConnect are vendor agnostic population health and care coordination solutions that compete directly with Allscripts dbMotion in smaller ambulatory facilities. 
  • Weak revenue cycle offering that they have struggled to sell internally; competes with Allscripts Payerpath. 


To view our analyst's original report on Wabtec click here. Below is an update on Wabtech (WAB) from a recent institutional research note written by Hedgeye Industrials Jay Van Sciver.


Should Have Been Discussed:

Given reports of DoJ concern that the Faiveley merger would reduce the number of passenger-train brake systems manufacturers from three to two, some management commentary was due on the call.  It is now increasingly clear that divestitures may be needed for LEY FP & WAB US to close.  Faiveley’s Braking & Safety Systems – the area most likely to generate overlap concern as we understand it – is about a quarter of LEY sales.  Divestitures would almost certainly undermine at least part of the strategic rationale for the transaction."


To view our analyst's original report on Lazard click hereBelow is an update from Financials analyst Jonathan Casteleyn.


It official. 2016 has surpassed 2014 as the worst year on record for withdrawn pending M&A transactions. With the Staples and Office Depot transaction nullified by the Department of Justice (DOJ) on Monday, another mid-size $6 billion was lost by the investment banking community. Only four months into the New Year, 2016 will likely finish by a wide margin as the worst period on record for lost M&A.


While the Department of Justice (DOJ) has kicked up its overview recently by blocking Halliburton/Baker Hughes as well, the recent 3rd iteration of the Treasury rules is making it harder for foreign and U.S. companies to redomicile into lower international tax jurisdictions. That's hurt as well. Both an active DOJ and the latest Treasury rules have brought announced M&A activity down by -20% year-over-year in 1Q16 decreasing pending pipelines throughout most of the industry including for our short idea, Lazard (LAZ).


Investing Ideas Newsletter - lazard


To view our analyst's original report on Deere & Company click here.


No update on Deere & Company (DE) ahead of the company's earnings next week but Hedgeye Industrials analyst Jay Van Sciver reiterates his short call. Stay tuned.

The Week Ahead

The Economic Data calendar for the week of the 16th of May through the 20th of May is full of critical releases and events. Here is a snapshot of some of the headline numbers that we will be focused on.



The Week Ahead - 05.13.16 Week Ahead

Daily Trading Ranges

20 Proprietary Risk Ranges

Daily Trading Ranges is designed to help you understand where you’re buying and selling within the risk range and help you make better sales at the top end of the range and purchases at the low end.

Cartoon of the Day: No Mirage

Cartoon of the Day: No Mirage - retail cartoon 05.13.2016


Despite Retail Sales numbers beating consensus estimates, the year-over-year growth numbers have been declining since the second half of 2014. Slower growth? That explains why retailers like Kohl's (KSS) and Nordstrom (JWN) got crushed this week. We reiterate our #ConsumerSlowing call.

McGough: Behind The Massive Spike In Retail Bankruptcies


In this brief excerpt from The Macro Show earlier today, Hedgeye Retail analyst Brian McGough explains why we’ve already seen more retail bankruptcies this year than in any full year in the last six.

Can Trump Unify The GOP? ... & The Clinton Super PAC

Editor's Note: Below is a brief excerpt from Hedgeye Potomac Chief Political Strategist JT Taylor's Morning Bullets sent to institutional clients each morning. For more information on how you can access our institutional research please email sales@hedgeye.com.


Can Trump Unify The GOP? ... & The Clinton Super PAC - paul ryan 23


For anyone expecting/hoping Trump would storm out of the RNC and take up an anti-Ryan Twitter rant, we're sorry to disappoint you.  For love of country, party, and dislike of both Democratic candidates, Speaker Paul Ryan and Donald Trump let the healing begin at yesterday's meeting on Capitol Hill without agreement on a number of core policy issues that divide them.


With the elections this fall impacting all three branches of government, we believe Ryan will gingerly board the Trump train to ensure that the Republicans are in the best possible position to defend his majority in the House as well as retain the Senate.


As Speaker of the House and the highest ranking elected Republican, we're not sure he ever had much choice.  We're also pretty sure not a day goes by that Ryan doesn't miss his old job as Chairman of the Ways & Means Committee - passing comprehensive tax reform is easy compared to navigating this election season.  


While Hillary Clinton has her hands full battling both Bernie Sanders and Trump, her supporters (read=superPACs) aim to win the war by defining Trump and running up his negatives on their terms - as he launches daily attacks on her.  The Clinton-allied superPACS are not about to make the same mistake as Trump's primary opponents by waiting too long to make the case against him and have taken to the airwaves with ad campaigns targeting the presumptive nominee. 


Can Trump Unify The GOP? ... & The Clinton Super PAC - bill clinton 23


While we expect the ultimate focus for the next six months to be Donald Trump vs. Hillary Clinton, Donald Trump vs. Bill Clinton has the potential to become the nastier of the two battles.  Trump has already pointed to Bill Clinton's pass indiscretions and is labeling Hillary Clinton "an enabler."  Trump was more than happy to drag family members into the mud during the primaries and we expect that to continue as he pivots to the general election.


One reporter put it recently, "Trump stoops to levels few are willing to stoop to. And often, this elicits an unwise overreaction."  Bill Clinton is still a highly popular, global statesman and, despite his history, is fiercely loyal to his wife and is quick to defend her when attacked.  The big question is whether he can or will maintain his statesman-like cool as Trump drags a graveyard full of personal skeletons out of the Clinton's closet. 

investing ideas

Risk Managed Long Term Investing for Pros

Hedgeye CEO Keith McCullough handpicks the “best of the best” long and short ideas delivered to him by our team of over 30 research analysts across myriad sectors.